Melanoma
If it’s your first time on this website, please read the disclaimer section.
Oct 12 – Oct 19, 2026
Expert Histopathologic Evaluation and Molecular Analyses for Ambiguous Cutaneous Melanocytic Tumors.
J CLIN ONCOL · Q1 JOURNAL - RANK #6/326TOP-TIER
This prospective cohort study evaluated a stepwise diagnostic approach combining expert histopathology and molecular analyses for ambiguous primary cutaneous melanocytic tumors. A definitive diagnosis was achieved in 97.2% of 994 patients, with 55.2% requiring molecular analyses. Nonmelanoma diagnoses (61.2%) showed no melanoma-related events over 5.4 years, while melanoma diagnoses (36.0%) had a 5.7% cumulative incidence of events over 5.0 years. This validated approach significantly improves accurate melanoma diagnosis, crucial for guiding appropriate patient management and ensuring timely cancer identification.
10.1200/JCO-26-00432
Sep 28 – Oct 05, 2026
Five-year survival with neoadjuvant therapy in melanoma: updated pooled analysis from the International Neoadjuvant Melanoma Consortium (INMC).
NAT MED · Q1 JOURNAL - RANK #1/195TOP-TIER
This pooled analysis of 1,038 patients with stage IIIB-D melanoma evaluated the five-year efficacy of neoadjuvant immune checkpoint inhibitors (ICIs) and targeted therapies across 26 international sites. Results showed that PD-1 plus immuno-oncology combinations achieved higher major pathological response (MPR) rates (61.4%) and superior five-year recurrence-free survival (73.9%) compared to PD-1 monotherapy or BRAF/MEK inhibitors. Notably, ICI-treated patients achieving MPR demonstrated exceptional five-year overall survival rates exceeding 97%, suggesting that adjuvant therapy may be unnecessary for this specific subgroup. These findings establish neoadjuvant ICI combinations as a highly effective standard for resectable melanoma, though poor outcomes with targeted therapies alone highlight the need for biomarker-driven treatment selection.
10.1038/s41591-026-04677-z
Cancer and the microbiome: from association to intervention.
LANCET ONCOL · Q1 JOURNAL - RANK #8/326TOP-TIER
This review synthesizes evidence regarding the gut microbiome’s role as a modifiable determinant of efficacy and toxicity in systemic cancer therapies, particularly immune checkpoint inhibitors (ICIs). Research indicates that higher microbial diversity and specific immunostimulatory pathways correlate with improved survival and treatment response in melanoma, non-small-cell lung cancer, and renal cell carcinoma. Conversely, the use of antibiotics and proton pump inhibitors is linked to inferior clinical outcomes due to microbiome disruption, while interventions like fecal microbiota transplantation are currently under investigation. These findings suggest that modulating the intestinal microbiome could optimize anticancer treatment responses, though therapeutic strategies remain in the investigational phase.
10.1016/S1470-2045(26)00326-8
Sep 21 – Sep 28, 2026
Transcriptomic Plasticity and Its Spatial Architecture Shape Melanoma Response to Immunotherapy and Its Combination With BRAF/MEKi.
J CLIN ONCOL · Q1 JOURNAL - RANK #6/326TOP-TIER
This study aimed to define tumor biology and identify biomarkers guiding treatment strategies for BRAF-mutant melanoma, integrating multi-omics data from large clinical cohorts and functional assays. Researchers identified two distinct ICB-resistant states: differentiated tumors, which benefited from BRAF/MEK inhibition combined with ICB, and undifferentiated tumors, less responsive to these combinations but showing sensitivity to anti-VEGF therapy retrospectively and CDK7 inhibition preclinically. These findings establish a transcriptional classification framework for melanoma, supporting biomarker-driven approaches to optimize therapeutic escalation by adding MAPK inhibition to ICB for specific patient subgroups. This has significant implications for personalized cancer treatment, addressing persistent unmet needs in melanoma management.
10.1200/JCO-25-02766
Aug 10 – Aug 17, 2026
Neoadjuvant Intralesional Daromun (L19IL2/L19TNF) in Resectable Locally Advanced Melanoma: An Update on the Efficacy and Safety Results of the PIVOTAL Phase III Trial.
J CLIN ONCOL · Q1 JOURNAL - RANK #6/326TOP-TIER
The PIVOTAL phase III trial investigated neoadjuvant intralesional Daromun (L19IL2/L19TNF) versus up-front surgery for 256 patients with resectable stage III melanoma. At a median 21-month follow-up, Daromun significantly improved recurrence-free survival (HR 0.59; p = .005) compared to up-front surgery. Updated analysis at 36.8 months confirmed clinically and statistically meaningful improvements in RFS and distant metastasis-free survival, with no new safety signals. This study directly addresses cancer treatment, offering a robust and effective neoadjuvant option for advanced melanoma, potentially improving patient outcomes by reducing disease recurrence and metastasis.
10.1200/JCO-26-00852